世界のNASH（非アルコール性脂肪性肝炎）バイオマーカー市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A13227 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療機器

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、NASH（非アルコール性脂肪性肝炎）バイオマーカーのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NASH（非アルコール性脂肪性肝炎）バイオマーカーの種類別市場規模（血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他）、用途別市場規模（製薬・CRO産業、病院、診断ラボ、学術研究機関）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・NASH（非アルコール性脂肪性肝炎）バイオマーカーの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：GENFIT SA、Gilead Sciences, Inc. (GILD)、AstraZeneca、Novartis AG、Bristol-Myers Squibb Company、Allergan Plc、Novo Nordisk A/S、Boehringer Ingelheim、Pfizer Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他 ・用途別分析2016年-2026年：製薬・CRO産業、病院、診断ラボ、学術研究機関 ・NASH（非アルコール性脂肪性肝炎）バイオマーカーの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・NASH（非アルコール性脂肪性肝炎）バイオマーカーのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・NASH（非アルコール性脂肪性肝炎）バイオマーカーのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・NASH（非アルコール性脂肪性肝炎）バイオマーカーの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・NASH（非アルコール性脂肪性肝炎）バイオマーカーの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The NASH (Non-alcoholic Steatohepatitis) Biomarkers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global NASH (Non-alcoholic Steatohepatitis) Biomarkers size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
NASH (Non-alcoholic Steatohepatitis) Biomarkers market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others

Market segment by Application can be divided into
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes

The key market players for global NASH (Non-alcoholic Steatohepatitis) Biomarkers market are listed below:
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe NASH (Non-alcoholic Steatohepatitis) Biomarkers product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers, with price, sales, revenue and global market share of NASH (Non-alcoholic Steatohepatitis) Biomarkers from 2019 to 2021.
Chapter 3, the NASH (Non-alcoholic Steatohepatitis) Biomarkers competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the NASH (Non-alcoholic Steatohepatitis) Biomarkers breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and NASH (Non-alcoholic Steatohepatitis) Biomarkers market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe NASH (Non-alcoholic Steatohepatitis) Biomarkers sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Serum Biomarkers
1.2.3 Hepatic Fibrosis Biomarkers
1.2.4 Apoptosis Biomarkers
1.2.5 Oxidative Stress Biomarkers
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Pharma & CRO Industry
1.3.3 Hospitals
1.3.4 Diagnostic Labs
1.3.5 Academic Research Institutes
1.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size & Forecast
1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value (2016-2026))
1.4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume (2016-2026)
1.4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2016-2026) & (USD/Unit)
1.5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity Analysis
1.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Total Production Capacity (2016-2026)
1.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
1.6.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
1.6.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Trends Analysis
2 Manufacturers Profiles
2.1 GENFIT SA
2.1.1 GENFIT SA Details
2.1.2 GENFIT SA Major Business
2.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Gilead Sciences, Inc. (GILD)
2.2.1 Gilead Sciences, Inc. (GILD) Details
2.2.2 Gilead Sciences, Inc. (GILD) Major Business
2.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Bristol-Myers Squibb Company
2.5.1 Bristol-Myers Squibb Company Details
2.5.2 Bristol-Myers Squibb Company Major Business
2.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Allergan Plc
2.6.1 Allergan Plc Details
2.6.2 Allergan Plc Major Business
2.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Novo Nordisk A/S
2.7.1 Novo Nordisk A/S Details
2.7.2 Novo Nordisk A/S Major Business
2.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.7.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Pfizer Inc
2.9.1 Pfizer Inc Details
2.9.2 Pfizer Inc Major Business
2.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturer
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Manufacturer (2019-2021e)
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in NASH (Non-alcoholic Steatohepatitis) Biomarkers
3.4 Market Concentration Rate
3.4.1 Top 3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer Market Share
3.4.2 Top 6 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer Market Share
3.5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region
4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2016-2026)
4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2016-2026)
4.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026)
4.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026)
4.4 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026)
4.5 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026)
4.6 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026)
5 Market Segment by Type
5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Type (2016-2026)
5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2016-2026)
5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Application (2016-2026)
6.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2016-2026)
6.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2026)
7.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2026)
7.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
7.3.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2016-2026)
7.3.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2026)
8.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2026)
8.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
8.3.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2016-2026)
8.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2026)
9.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2026)
9.3 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region
9.3.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2026)
10.2 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2026)
10.3 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
10.3.1 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2016-2026)
10.3.2 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2026)
11.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2026)
11.3 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
11.3.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Distributors
12.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type, (USD Million), 2021-2026
Table 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application, (USD Million), 2021-2026
Table 3. GENFIT SA Basic Information, Manufacturing Base and Competitors
Table 4. GENFIT SA Major Business
Table 5. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 6. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Gilead Sciences, Inc. (GILD) Basic Information, Manufacturing Base and Competitors
Table 8. Gilead Sciences, Inc. (GILD) Major Business
Table 9. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 10. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 12. AstraZeneca Major Business
Table 13. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 14. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 16. Novartis AG Major Business
Table 17. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 18. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 20. Bristol-Myers Squibb Company Major Business
Table 21. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 22. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Allergan Plc Basic Information, Manufacturing Base and Competitors
Table 24. Allergan Plc Major Business
Table 25. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 26. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 28. Novo Nordisk A/S Major Business
Table 29. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 30. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 32. Boehringer Ingelheim Major Business
Table 33. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 34. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Inc Major Business
Table 37. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 38. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturer (2019-2021e) & (K Units)
Table 40. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 41. Market Position of Manufacturers in NASH (Non-alcoholic Steatohepatitis) Biomarkers, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 42. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Site of Key Manufacturer
Table 44. NASH (Non-alcoholic Steatohepatitis) Biomarkers New Entrant and Capacity Expansion Plans
Table 45. NASH (Non-alcoholic Steatohepatitis) Biomarkers Mergers & Acquisitions in the Past Five Years
Table 46. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2016-2021e) & (K Units)
Table 47. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2021-2026) & (K Units)
Table 48. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2016-2021e) & (USD Million)
Table 49. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2021-2026) & (USD Million)
Table 50. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 51. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 52. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2016-2021e) & (USD Million)
Table 53. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2021-2026) & (USD Million)
Table 54. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2016-2021e) & (USD/Unit)
Table 55. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2021-2026) & (USD/Unit)
Table 56. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 57. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 58. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2016-2021e) & (USD Million)
Table 59. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2021-2026) & (USD Million)
Table 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2016-2021e) & (USD/Unit)
Table 61. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2021-2026) & (USD/Unit)
Table 62. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2016-2021e) & (K Units)
Table 63. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2021-2026) & (K Units)
Table 64. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2021e) & (USD Million)
Table 65. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2021-2026) & (USD Million)
Table 66. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 67. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 68. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 69. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 70. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2016-2021e) & (K Units)
Table 71. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2021-2026) & (K Units)
Table 72. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2021e) & (USD Million)
Table 73. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2021-2026) & (USD Million)
Table 74. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 75. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 76. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 77. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 78. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2016-2021e) & (K Units)
Table 79. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2021-2026) & (K Units)
Table 80. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2016-2021e) & (USD Million)
Table 81. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2021-2026) & (USD Million)
Table 82. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 83. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 84. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 85. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 86. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2016-2021e) & (K Units)
Table 87. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2021-2026) & (K Units)
Table 88. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2021e) & (USD Million)
Table 89. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2021-2026) & (USD Million)
Table 90. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 91. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 92. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 93. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 94. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2016-2021e) & (K Units)
Table 95. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2021-2026) & (K Units)
Table 96. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2016-2021e) & (USD Million)
Table 97. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2021-2026) & (USD Million)
Table 98. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2016-2021e) & (K Units)
Table 99. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2021-2026) & (K Units)
Table 100. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2016-2021e) & (K Units)
Table 101. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2021-2026) & (K Units)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Distributors
Table 105. NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Customers
List of Figures
Figure 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Picture
Figure 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type in 2020
Figure 3. Serum Biomarkers
Figure 4. Hepatic Fibrosis Biomarkers
Figure 5. Apoptosis Biomarkers
Figure 6. Oxidative Stress Biomarkers
Figure 7. Others
Figure 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application in 2020
Figure 9. Pharma & CRO Industry
Figure 10. Hospitals
Figure 11. Diagnostic Labs
Figure 12. Academic Research Institutes
Figure 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (2016-2026) & (K Units)
Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2016-2026) & (USD/Unit)
Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity (2016-2026) & (K Units)
Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
Figure 21. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends
Figure 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturer in 2020
Figure 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Manufacturer in 2020
Figure 24. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer (Revenue) Market Share in 2020
Figure 27. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2016-2026)
Figure 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2016-2026)
Figure 29. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026) & (USD Million)
Figure 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026) & (USD Million)
Figure 32. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2016-2026) & (USD Million)
Figure 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2016-2026)
Figure 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2016-2026)
Figure 36. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2016-2026) & (USD/Unit)
Figure 37. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 38. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2016-2026)
Figure 39. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2016-2026) & (USD/Unit)
Figure 40. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2016-2026)
Figure 41. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 42. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2016-2026)
Figure 43. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2016-2026)
Figure 44. United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2016-2026)
Figure 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2016-2026)
Figure 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2016-2026)
Figure 51. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2016-2026)
Figure 60. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2016-2026)
Figure 67. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 68. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2016-2026)
Figure 69. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2016-2026)
Figure 70. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2016-2026)
Figure 76. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source

---